The New England Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (NERCE) has become a focal point for research and development in biodefense and emerging infectious diseases, developing novel approaches to treatment and prevention of infections. NERCE has supported and its core labs have been utilized by scientists from academia, the public health sector and the biopharmaceutical and biotechnology industries based in New England and across the country. The center functions as a catalyst for basic, translational and clinical research scientists to conduct research leading to new products directed against infectious disease. NERCE will continue this mission by supporting research addressing three primary themes - "Highly Pathogenic RNA Viruses", "Bacterial Toxins and other Pathogenic Proteins", and "Gram-Negative Bacteria - Pathogenesis and Immunity". The Center will continue its emphasis on "Chemical Biology" and high throughput approaches to experimental discovery. NERCE will also be supporting five core labs - "Microbiology and Animal Resources", "Biomolecule Production", "Small Molecule Screening", "Target Identification", and "Molecular Imaging". These core resources are available to the entire New England infectious disease community working on NIAID priority pathogens and agents of emerging infectious disease. The small molecule screening core (National Screening Laboratory for the Research Centers of Excellence in Biodefense and Emerging Infectious Diseases Research, or NSRB) supports scientists affiliated with any of the ten Regional Centers. NERCE will also continue its Developmental Projects program and Career Development in Biodefense program in an effort to initiate new research efforts and to attract new investigators to this field.
The programs supported through the New England RCE will provide the basic knowledge necessary for development of therapeutics, vaccines, and diagnostics directed against biodefense and emerging infectious disease pathogens. These programs will also provide training opportunities for investigators entering and active in the field.
|Clark, Margaret J; Miduturu, Chandra; Schmidt, Aaron G et al. (2016) GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein. Cell Chem Biol 23:443-52|
|Russo, Brian C; Stamm, Luisa M; Raaben, Matthijs et al. (2016) Intermediate filaments enable pathogen docking to trigger type 3 effector translocation. Nat Microbiol 1:16025|
|Kirienko, Daniel R; Revtovich, Alexey V; Kirienko, Natalia V (2016) A High-Content, Phenotypic Screen Identifies Fluorouridine as an Inhibitor of Pyoverdine Biosynthesis and Pseudomonas aeruginosa Virulence. mSphere 1:|
|Taylor, Travis J; Diaz, Fernando; Colgrove, Robert C et al. (2016) Production of immunogenic West Nile virus-like particles using a herpes simplex virus 1 recombinant vector. Virology 496:186-93|
|Chou, Yi-ying; Cuevas, Christian; Carocci, Margot et al. (2016) Identification and Characterization of a Novel Broad-Spectrum Virus Entry Inhibitor. J Virol 90:4494-510|
|Mellata, Melha; Mitchell, Natalie M; SchÃ¶del, Florian et al. (2016) Novel vaccine antigen combinations elicit protective immune responses against Escherichia coli sepsis. Vaccine 34:656-62|
|Helenius, Iiro Taneli; Nair, Aisha; Bittar, Humberto E Trejo et al. (2016) Focused Screening Identifies Evoxine as a Small Molecule That Counteracts CO2-Induced Immune Suppression. J Biomol Screen 21:363-71|
|Stone, Laura K; Baym, Michael; Lieberman, Tami D et al. (2016) Compounds that select against the tetracycline-resistance efflux pump. Nat Chem Biol 12:902-904|
|Balasubramanian, Anuradha; Manzano, Mark; Teramoto, Tadahisa et al. (2016) High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease. Antiviral Res 134:6-16|
|Vrentas, Catherine E; Moayeri, Mahtab; Keefer, Andrea B et al. (2016) A Diverse Set of Single-domain Antibodies (VHHs) against the Anthrax Toxin Lethal and Edema Factors Provides a Basis for Construction of a Bispecific Agent That Protects against Anthrax Infection. J Biol Chem 291:21596-21606|
Showing the most recent 10 out of 401 publications